SVRA
Savara Inc.- Healthcare
- Biotechnology
- $867M market cap
Forecast run · Oct 29, 2026Upside rank 1699 of 3,186
Model Signal
ForecastQ Daily Probabilities
24.1%
67.6%
15.2%
Analyst Consensus
Recommendation2.18/5 Buy
Last price$4.22
Price target$10.00
Implied move+137.0%
Analysts11
ForecastQ Portfolios
SVRA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.